Alnylam Pharmaceuticals reported a strategic collaboration with Inceptive Nucleics that will pair the biotech company's RNAi research platform with Inceptive’s generative artificial intelligence models to accelerate discovery of oligonucleotide therapies. The announcement coincided with a 2.5% rise in Alnylam shares in after-hours trading on Wednesday.
Under the agreement, Alnylam will provide $30 million in upfront consideration, which includes both cash and an equity component. Inceptive will also be eligible to receive additional payments tied to preclinical, regulatory and commercial sales milestones, with total potential payments under the collaboration reaching up to $2 billion.
The stated aim of the partnership is to integrate Inceptive’s foundation models into Alnylam’s research and development workflows as part of the company’s Alnylam 2030 strategy. Specifically, the collaboration is focused on improving and accelerating small interfering RNA - siRNA - design by using AI to model target messenger RNAs, explore sequence space and evaluate chemical modifications intended to enhance potency and efficacy.
Inceptive describes its foundation model as adaptable across therapeutic modalities without the need for retraining. In preliminary joint exploratory work with Alnylam, the model reportedly reached useful performance within weeks and revealed biological insights from small datasets that helped characterize siRNA molecules, which are the active components of RNAi therapeutics.
The deal also provides Alnylam with access to Inceptive’s AI expertise and personnel, including CEO Jakob Uszkoreit, who is noted as a co-inventor of the Transformer architecture. From Alnylam’s side, the company brings a track record of six approved drugs and more than 20 years of proprietary siRNA data to the collaboration.
Alnylam framed the collaboration as a means to better prioritize promising molecules and raise experimental productivity by predicting which therapeutic candidates are most likely to perform well in preclinical models, so those candidates can be advanced for further development.
Context and next steps
Both parties appear to position the collaboration as an integration of domain-specific data and generative AI capabilities to shorten discovery timelines and refine candidate selection. The financial structure ties a portion of Inceptive’s compensation to scientific and commercial milestones, linking payment to demonstrated progress in preclinical, regulatory and market outcomes.
How quickly and broadly the AI-driven designs translate into validated preclinical successes, regulatory milestones and eventual commercial sales will determine the size and timing of milestone payments.